Astonea Labs Limited, a reputed name in the pharmaceutical and cosmetic product manufacturing industry, is launching its initial public offering (IPO) from May 27, 2025, to May 29, 2025. The company is offering a fresh issue worth ₹37.66 Crores through the Book Building method, comprising 27.90 lakh equity shares. The shares will be listed on the BSE SME platform, with allotment expected on May 30, 2025, and tentative listing on June 3, 2025.

The IPO price band is fixed between ₹128 to ₹135 per share. Investors must bid in multiples of 1,000 shares, which means the minimum investment required for retail investors is ₹1,35,000. High Net Worth Individuals (HNIs) are required to bid for at least two lots, amounting to ₹2,70,000.

Company Profile and Product Range

Astonea Labs specializes in manufacturing and marketing an extensive portfolio of pharmaceutical and cosmetic products. Their pharma range includes antibiotics, anti-cold medications, antihistamines, diabetic drugs, cardiovascular medicines, gynecological drugs, analgesics, antifungal medications, and multivitamins. Besides pharmaceuticals, the company also markets skin, tooth, and hair care products in various forms such as gels, ointments, creams, lotions, oils, and serums. This diversified product base caters to both domestic and international markets, showcasing the company’s robust manufacturing capabilities.

Financial Performance and Market Capitalization

At the upper band of ₹135 per share, the company’s market capitalization is estimated at ₹141.89 Crores post-IPO. The IPO has attracted considerable interest from Anchor Investors, raising ₹10.66 Crores via the allocation of 7,90,000 equity shares at ₹135 per share. This anchor investor participation signals confidence in the company’s prospects.

IPO Grey Market Premium (GMP)

The Grey Market Premium for Astonea Labs IPO currently stands at ₹0, indicating a neutral market sentiment based on company fundamentals and demand-supply dynamics. Investors should note that GMP figures reflect unofficial and unregulated markets and are not a guaranteed indicator of listing performance.

Live IPO Subscription Status

As of the evening of May 29, 2025, the IPO has been subscribed 2.44 times, reflecting strong demand, especially from retail and institutional investors. Investors keen on subscribing should consider this oversubscription trend before applying.

Use of IPO Proceeds

The company plans to deploy the funds raised through the IPO for strategic growth and operational improvements:

1. ₹128.97 Lakh for product registration expenses in Bolivia, South America, aimed at expanding global footprint.

2. ₹523.40 Lakh for purchasing and installing advanced plant and machinery for ointment production aligned with international export standards.

3. ₹495.15 Lakh dedicated to advertising, marketing, and brand building initiatives to enhance market presence.

4. ₹68.38 Lakh invested in procuring necessary hardware and software for operational efficiency.

5. ₹1,975.00 Lakh earmarked for working capital requirements to support business expansion.

6. The balance amount will be utilized for general corporate purposes.

How to Check Astonea Labs IPO Allotment Status

The allotment will be finalized and published on May 30, 2025. Investors can check their allotment status using the following steps:

• Visit the registrar’s IPO allotment status page.

• Select “Astonea Labs Limited IPO” from the dropdown list.

• Enter your application number, PAN, or DP Client ID.

• Submit the details to view the allotment status.

This simple process enables investors to confirm their share allocation efficiently.

Book Running Lead Manager and Registrar

The Book Running Lead Manager (BRLM) for the IPO is ONEVIEW CORPORATE ADVISORS PRIVATE LIMITED, entrusted with managing the issue process. The registrar is KFin Technologies Limited, responsible for handling investor queries and share allotment processes. The Market Maker role is held by Basan Equity Broking Limited, ensuring liquidity post-listing.

Conclusion and Investment Outlook

Astonea Labs’ IPO presents a compelling opportunity for investors looking to enter the pharmaceutical manufacturing sector with a company demonstrating diverse product offerings and global aspirations. The healthy subscription numbers and anchor investor confidence suggest positive market reception.

Given the neutral GMP and a strong financial outlook, investors should carefully evaluate their risk appetite. The IPO’s proceeds will fuel expansion, especially into export markets, which could unlock future growth potential. Retail investors and HNIs are advised to consider this IPO for long-term value creation

.

The Upcoming IPOs in this week and coming weeks are Ganga Bath Fittings, Victory Electric Vehicles International, Wagons Learning.

The Current active IPO are 3B Films, N R Vandana Tex Industries, Scoda Tubes, Neptune Petrochemicals.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.